Form 4 holding
Chief Scientific Officer
Aclaris Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 265,662
- Estimated value
- $528,667
- Report date
- 01 Mar 2025
- Price
- $1.99
- Ownership
- Direct
Joseph Monahan
Insider Reports History
- Reporting-owner location
- Wayne, PA
- Latest reporting-owner signature
-
/s/ Matthew Rothman, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Joseph Monahan
Form 4 holding
Chief Scientific Officer
Aclaris Therapeutics, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 10,925
- Estimated value
- $21,741
- Report date
- 01 Mar 2025
- Price
- $1.99
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Scientific Officer
Aclaris Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 193
- Estimated value
- $384
- Report date
- 01 Mar 2025
- Price
- $1.99
- Ownership
- By Spouse
Form 4 holding
Chief Scientific Officer
Aclaris Therapeutics, Inc.
- Security class
- Employee Stock Option (Right to Buy)
- Shares / value
- 293,500
- Estimated value
- Report date
- 03 Feb 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Joseph Monahan
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Mar 2025
- Transactions
- 5
- Transaction value
- -$54,243
- Accepted by SEC
- 04 Mar 2025, 16:15
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Feb 2025
- Transactions
- 7
- Transaction value
- -$28,066
- Accepted by SEC
- 04 Feb 2025, 16:15
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 31 Dec 2024
- Transactions
- 7
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2025, 18:25
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 10 Dec 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Dec 2024, 16:15
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Mar 2024
- Transactions
- 9
- Transaction value
- -$26,391
- Accepted by SEC
- 05 Mar 2024, 17:04
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Feb 2024
- Transactions
- 6
- Transaction value
- -$3,100
- Accepted by SEC
- 05 Feb 2024, 19:31
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 23 Oct 2023
- Transactions
- 1
- Transaction value
- -$30,460
- Accepted by SEC
- 25 Oct 2023, 16:28
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 21 Aug 2023
- Transactions
- 1
- Transaction value
- -$43,895
- Accepted by SEC
- 22 Aug 2023, 16:31
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 20 Jun 2023
- Transactions
- 1
- Transaction value
- -$61,663
- Accepted by SEC
- 22 Jun 2023, 16:30
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Mar 2023
- Transactions
- 10
- Transaction value
- -$385,639
- Accepted by SEC
- 03 Mar 2023, 19:12
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 15 Feb 2023
- Transactions
- 1
- Transaction value
- -$65,310
- Accepted by SEC
- 17 Feb 2023, 15:34
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Feb 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Feb 2023, 16:07
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 15 Dec 2022
- Transactions
- 1
- Transaction value
- -$79,412
- Accepted by SEC
- 16 Dec 2022, 15:57
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 17 Oct 2022
- Transactions
- 1
- Transaction value
- -$79,908
- Accepted by SEC
- 19 Oct 2022, 16:45
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 18 Apr 2022
- Transactions
- 1
- Transaction value
- -$488,298
- Accepted by SEC
- 20 Apr 2022, 17:06
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 10 Mar 2022
- Transactions
- 1
- Transaction value
- -$426,803
- Accepted by SEC
- 14 Mar 2022, 16:53
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Mar 2022
- Transactions
- 8
- Transaction value
- $0
- Accepted by SEC
- 03 Mar 2022, 17:11
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 09 Feb 2022
- Transactions
- 1
- Transaction value
- -$4,857
- Accepted by SEC
- 11 Feb 2022, 15:22
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Feb 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Feb 2022, 15:49
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Sep 2021
- Transactions
- 3
- Transaction value
- -$17,926
- Accepted by SEC
- 02 Sep 2021, 17:39
- Role
- Chief Scientific Officer
- Next action
- Open filing details
4
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 01 Jun 2021
- Transactions
- 4
- Transaction value
- -$471,437
- Accepted by SEC
- 02 Jun 2021, 21:45
- Role
- Chief Scientific Officer
- Next action
- Open filing details
3
ACRS
Aclaris Therapeutics, Inc.
- Report period
- 05 May 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 17 May 2021, 18:06
- Role
- Chief Scientific Officer
- Next action
- Open filing details